RxDoctor Payments Data

Mital Sheth, MD

Cardiovascular Disease · Philadelphia, PANPI 1053607606

Payments from drug & device makers

$559in general payments, 2019–2025

Across 27 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$178
  • Amgen$82
  • Novartis$81
  • Novo Nordisk$46
  • Pfizer$39
  • Johnson & Johnson$38
  • plus $96 from 4 others

What the payments were for

  • Food & beverage$559100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim7$178
Amgen5$82
Novartis4$81
Novo Nordisk2$46
Pfizer2$39
Johnson & Johnson2$38
E.r. Squibb & Sons, L.L.C.2$33
Watermark Medical, Inc.1$28
Preventice Services, LLC1$17
Merck1$17

How this compares

$559 in reported general payments places this provider in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$117,660
Medicare patients
363
Services billed
1,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$111,219
Repatha SureclickEvolocumab28$20,385
XareltoRivaroxaban15$8,346
Atorvastatin Calcium207$2,654
Ezetimibe45$1,927
Metoprolol Succinate149$1,850
Rosuvastatin Calcium64$1,454
Amlodipine Besylate178$1,154
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$920
Lisinopril60$757
Losartan Potassium37$558
Furosemide67$495
ClopidogrelClopidogrel Bisulfate43$444
Carvedilol25$344
Isosorbide Mononitrate ErIsosorbide Mononitrate22$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$111,219134 claims
Johnson & JohnsonXarelto$38$8,34615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →